Medigen Vaccine Biologics - Public Comps and Valuation Multiples

Medigen Vaccine Biologics Overview

About Medigen Vaccine Biologics

Medigen Vaccine Biologics Corp is a biopharmaceutical company focusing on developing and producing vaccines and biologics. It is engaged in developing IP-protected cell-culture technologies for vaccine manufacturing. The company develops vaccines and affordable biosimilars to prevent regional infectious diseases. The group generates revenue from manufacturing and selling a range of COVID-19 vaccines and COVID-19 test kits and provides technical services on cellular therapy product quality and cell culture tests.

Founded

2012

HQ

Employees

129

Website

medigenvac.com

Sectors

Vaccines & Immunotherapies
Biopharmaceuticals
BioTech

Financials

Last FY Revenue $19.2M

Last FY EBITDA $2.4M

EV

$356M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Medigen Vaccine Biologics Financials

See Medigen Vaccine Biologics valuation multiples based on analyst estimates

Medigen Vaccine Biologics P&L

In the most recent fiscal year, Medigen Vaccine Biologics reported revenue of $19.2M and EBITDA of $2.4M.

Medigen Vaccine Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Medigen Vaccine Biologics valuation multiples based on analyst estimates

	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	XXX	$19.2M	XXX	XXX	XXX
Gross Profit	XXX	$12.6M	XXX	XXX	XXX
Gross Margin	XXX	65%	XXX	XXX	XXX
EBITDA	XXX	$2.4M	XXX	XXX	XXX
EBITDA Margin	XXX	12%	XXX	XXX	XXX
EBIT	XXX	-$4.6M	XXX	XXX	XXX
EBIT Margin	XXX	-24%	XXX	XXX	XXX
Net Profit	XXX	-$2.6M	XXX	XXX	XXX
Net Margin	XXX	-13%	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Medigen Vaccine Biologics including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Medigen Vaccine Biologics achieved $19.2M in revenue and $2.4M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	Analyst estimates available to subscribers	$19.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$12.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	65.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$2.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	12.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	-$4.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	-24.1% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	-$2.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	-13.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Medigen Vaccine Biologics

This financial data table provides comprehensive performance metrics for Medigen Vaccine Biologics, a company based in Taiwan. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Medigen Vaccine Biologics reported $19.2M in total revenue.
Fiscal year EBITDA was $2.4M.
The company maintained a gross profit margin of 65.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was 12.4%.
Net profit margin reached -13.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Medigen Vaccine Biologics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Medigen Vaccine Biologics Stock Performance

Medigen Vaccine Biologics has current market cap of TWD 12.6B (or $399M), and EV of TWD 11.2B (or $356M).

Market Cap Evolution

Medigen Vaccine Biologics Stock Data

As of January 16, 2026, Medigen Vaccine Biologics's stock price is TWD 38 (or $1).

See Medigen Vaccine Biologics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$356M	$399M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Medigen Vaccine Biologics Valuation Multiples

Medigen Vaccine Biologics's trades at 18.5x EV/Revenue multiple, and 149.5x EV/EBITDA.

See valuation multiples for Medigen Vaccine Biologics and 15K+ public comps

Medigen Vaccine Biologics Financial Valuation Multiples

As of January 16, 2026, Medigen Vaccine Biologics has market cap of $399M and EV of $356M.

Equity research analysts estimate Medigen Vaccine Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Medigen Vaccine Biologics's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$399M	XXX	$399M	XXX	XXX	XXX
EV (current)	$356M	XXX	$356M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	18.5x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	149.5x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	-76.9x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	-156.3x	XXX	XXX	XXX
EV/FCF	n/a	XXX	1939.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Medigen Vaccine Biologics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Medigen Vaccine Biologics Margins & Growth Rates

Medigen Vaccine Biologics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Medigen Vaccine Biologics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Medigen Vaccine Biologics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Medigen Vaccine Biologics and other 15K+ public comps

Medigen Vaccine Biologics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	37%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	37%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	90%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial